BioMarin Pharma (BMRN) Tops Q3 EPS by 15c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $56.56 +1.18%
Revenue Growth %: +13.2%
Financial Fact:
Equity in the loss of BioMarin/Genzyme LLC: -104K
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +13.2%
Financial Fact:
Equity in the loss of BioMarin/Genzyme LLC: -104K
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.07), $0.15 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $391.7 million versus the consensus estimate of $367.09 million.
GUIDANCE:
BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion, versus the consensus of $1.51 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
- Jabil (JBL) Tops Q3 EPS by 8c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
